PTGER4 gene variant rs76523431 is a candidate risk factor for radiological joint damage in rheumatoid arthritis patients: A genetic study of six cohorts by Rodriguez-Rodriguez, Luis et al.
RESEARCH ARTICLE Open Access
PTGER4 gene variant rs76523431 is a
candidate risk factor for radiological joint
damage in rheumatoid arthritis patients: a
genetic study of six cohorts
Luis Rodriguez-Rodriguez1*, Jose Ivorra-Cortes2, F. David Carmona3, Javier Martín3, Alejandro Balsa4,
Hanna W. van Steenbergen5, Annette H. M. van der Helm-van Mil5, Isidoro González-Álvaro6
and Benjamín Fernandez-Gutiérrez1
Abstract
Introduction: Prostaglandin E receptor 4 (PTGER4) is implicated in immune regulation and bone metabolism. The
aim of this study was to analyze its role in radiological joint damage in rheumatoid arthritis (RA).
Methods: Six independent cohorts of patients with RA of European or North American descent were included,
comprising 1789 patients with 5083 sets of X-rays. The Hospital Clínico San Carlos Rheumatoid Arthritis, Princesa
Early Arthritis Register Longitudinal study, and Hospital Universitario de La Paz early arthritis (Spain) cohorts were
used as discovery cohorts, and the Leiden Early Arthritis Clinic (The Netherlands), Wichita (United States), and
National Databank for Rheumatic Diseases (United States and Canada) cohorts as replication cohorts. First, the
PTGER4 rs6896969 single-nucleotide polymorphism (SNP) was genotyped using TaqMan assays and available
Illumina Immunochip data and studied in the discovery and replication cohorts. Second, the PTGER4 gene and
adjacent regions were analyzed using Immunochip genotyping data in the discovery cohorts. On the basis of
pooled p values, linkage disequilibrium structure of the region, and location in regions with transcriptional
properties, SNPs were selected for replication. The results from discovery, replication, and overall cohorts were
pooled using inverse-variance–weighted
meta-analysis. Influence of the polymorphisms on the overall radiological damage (constant effect) and on damage
progression over time (time-varying effect) was analyzed.
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Results: The rs6896969 polymorphism showed a significant association with radiological damage in the constant
effect pooled analysis of the discovery cohorts, although no significant association was observed in the replication
cohorts or the overall pooled analysis. Regarding the analysis of the PTGER4 region, 976 variants were analyzed in
the discovery cohorts. From the constant and time-varying effect analyses, 12 and 20 SNPs, respectively, were
selected for replication. Only the rs76523431 variant showed a significant association with radiographic progression
in the time-varying effect pooled analysis of the discovery, replication, and overall cohorts. The overall pooled effect
size was 1.10 (95 % confidence interval 1.05–1.14, p = 2.10 × 10−5), meaning that radiographic yearly progression
was 10 % greater for each copy of the minor allele.
Conclusions: The PTGER4 gene is a candidate risk factor for radiological progression in RA.
Keywords: Rheumatoid arthritis, Polymorphism, Radiological joint damage, PTGER4, rs76523431
Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune
disease that affects between 0.5 % and 1 % of the popula-
tion in developed countries. It is a complex genetic con-
dition with several patterns of progression [1] potentially
associated with significant morbidity, disability, and
costs to society [2]. Bearing this in mind, it would be
useful to identify those patients at higher risk of severe
disease, because early treatment could ameliorate its
prognosis [3]. Genetic polymorphisms could be used as
molecular biomarkers to predict disease development
and to anticipate the clinical subset in which a particular
patient will be included. Furthermore, radiological dam-
age can be considered an objective measure of RA sever-
ity because the extent of joint destruction, measured
using radiographic scores such as the Sharp/van der
Heijde score (SHS), reflects the cumulative burden of
inflammation.
Prostaglandin E receptor 4 (PTGER4, EP4), located at
5p13.1, encodes one of the four receptors identified for
prostaglandin E2. This receptor is a member of the G
protein–coupled receptor family, and it is expressed in
several cell types, including T cells, macrophages, and
synovial fibroblasts. This receptor has been implicated
both in immune regulation and in bone metabolism.
Together with another prostaglandin E2 receptor (EP2), it
regulates the production of proinflammatory factors [such
as interleukin (IL)-6, macrophage colony-stimulating fac-
tor, and vascular endothelial growth factor] in response to
IL-1β in human synovial fibroblasts [4, 5]. This receptor
also enhances T helper cell type 1 (Th1) differentiation
and promotes Th17 cell expansion through the induction
of IL-23 secretion by dendritic cells [6–8], leading to
enhanced IL-17 expression and the accumulation of Th17
cells [6, 9]. Moreover, it was observed that the lack of EP2
and EP4 [5, 10] or the use of EP4 antagonists [7, 8] reduces
the severity and suppresses the disease progression in
mice subjected to experimentally induced arthritis and
experimental autoimmune encephalomyelitis. EP4 also
induces bone remodeling, both stimulating de novo bone
formation [11] and, in parallel, increasing the number of
osteoclasts through the induction of receptor activator of
nuclear factor κB ligand [12, 13]. It also induces the
production of parathyroid hormone-related peptide in RA
fibroblasts treated with IL-1α [14].
Taking into account the pleiotropic effects of PTGER4,
the objective of our present study was to assess the role
of this receptor in RA disease severity. To that end, and
considering the overlap of genetic loci between different
immune-mediated diseases [15], we initially analyzed the
association between the PTGER4 rs6896969 single-
nucleotide polymorphism (SNP) and radiological joint
damage in patients with RA. This variant had previously
been associated with multiple sclerosis [16]. Subsequently,
we performed a more thorough analysis of the PTGER4
region using available Immunochip data (Illumina, San
Diego, CA, USA).
Methods
Study population
All the patients included in this study were of European
or North American descent and had been diagnosed with
RA according to the 1987 classification criteria of the
American College of Rheumatology [17]. For the identifi-
cation part of our study, we used three Spanish cohorts
(referred to as the discovery cohorts): the Hospital Clínico
San Carlos Rheumatoid Arthritis cohort (HCSC-RAC,
Madrid, Spain) [18], the Princesa Early Arthritis Register
Longitudinal study (PEARL, Madrid, Spain) [19], and the
Hospital Universitario de La Paz early arthritis cohort
(PAZ, Madrid, Spain) [20]. The discovery cohort com-
prised 525 patients with 1020 sets of X-rays. For the repli-
cation part of the study, we used three cohorts (referred
to as the replication cohorts): the Leiden Early Arthritis
Clinic cohort (EAC, Leiden, The Netherlands) [21], the
Wichita cohort (Wichita, KS, USA) [22], and the National
Databank for Rheumatic Diseases (NDB; United States
and Canada) [23]. The replication cohorts comprised 1264
patients with 4063 sets of X-rays. Altogether, we included
1789 patients with 5083 sets of X-rays in this study.
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Study approval was given by the local medical ethics
committee of each participating center. Written in-
formed consent was obtained from all participants.
Variables
Radiographic joint damage was assessed using the SHSs
of hands and wrists in the HCSC-RAC, PEARL, PAZ,
Wichita, and NDB cohorts. SHSs of hands, wrist, and
feet were obtained from the EAC cohort. This method
scores both the presence and extent of erosions (scored
in 16 areas of the hands and wrists on a scale of 0–5,
and in 6 areas of the feet on a scale of 0–10), as well as
narrowing and (sub)luxation of the joint (scored in 15
areas of the hands and wrists and in 6 areas of the feet,
both on a scale of 0–4). The maximum erosion scores
are 160 in hands and wrists and 120 in the feet, with
maximum narrowing/(sub)luxation of 120 and 48, re-
spectively. Total scores range from 0 to 280 for erosions
and from 0 to 168 for narrowing/(sub)luxation. X-rays
from each cohort were scored by different well-trained
readers. Observers did not have access to the identity,
clinic, or genetic data of the patients. The HCSC-RAC,
PEARL, PAZ, EAC, and Wichita cohorts had serial X-rays
that were chronologically scored, whereas the NDB cohort
had only one set of X-rays per patient. The intraclass
correlation coefficient (ICC) was assessed by twice reading
10 % of the radiographs. The ICCs of the HCSC-RAC,
PEARL, PAZ, EAC, Wichita, and NDB cohorts were 0.99,
0.99, 0.98, 0.91, 0.98, and 0.98, respectively.
Patients’ clinical records were reviewed, and the
following demographic and clinical variables were col-
lected: sex, age at RA diagnosis, presence of rheumatoid
factor (except for the Wichita and NDB cohorts), and
anticitrullinated peptide antibodies (ACPA). Year at RA
diagnosis was used as a surrogate marker for initial RA
treatment in the HCSC-RAC, PEARL, PAZ, and EAC
cohorts, as different strategies were implemented during
different time periods. In the HCSC-RAC, PEARL, and
PAZ cohorts, patients included before 1990 were initially
treated with nonsteroidal anti-inflammatory drugs
(NSAIDs). Between 1990 and 1999, initial treatment was
monotherapy. Between 2000 and 2004, both combin-
ation therapy and biologic drugs started to be used. Be-
ginning in 2005, the use of combination therapy and
biologic drugs became widespread. In the EAC cohort,
patients included in 1993–1995 were initially treated
with NSAIDs; patients included in 1996–1998 were ini-
tially treated with hydroxychloroquine or sulfasalazine;
and patients included in 1999–2006 were promptly
treated with methotrexate [21]. Therefore, year at RA
diagnosis was categorized for the HCSC-RAC, PEARL,
and PAZ cohorts in the following periods: before
1990, 1990–1999, 2000-2004, and after 2004. For the
EAC cohort, year at RA diagnosis was categorized as
1993–1995, 1996–1998, and 1999–2006. In the Wichita
and NDB cohorts, year at RA diagnosis was not used as a
surrogate marker for initial RA treatment, as most pa-
tients were diagnosed before the use of tailored therapy or
biologics became widespread and initial treatment was ra-
ther homogeneous in each cohort.
Genotyping
In the HCSC-RAC cohort, subjects were genotyped for
the rs6896969 SNP using TaqMan Assays-on-Demand
from Applied Biosystems (Foster City, CA, USA) accord-
ing to the manufacturer’s protocol. The results were
analyzed using the 7900HT Fast Real-Time PCR System
(Applied Biosystems). Doubtful calls were manually
checked.
Illumina Immunochip, a high-density throughput array
designed to fine-map immune-related loci [24], was used
to obtain genotyping data from the rs6896969 SNP in
the PEARL, PAZ, EAC, Wichita, and NDB cohorts. Also,
it was used to obtain genotyping data from the PTGER4
gene and adjacent regions in all six cohorts. We selected
a wide area around PTGER4, from 38,957,820 bp to
41,336,050 bp (GRCh37/hg19) (see Additional file 1:
Figure S1). In the discovery cohorts, genotype data was
quality-filtered using the following criteria: success call
rate per individual and success call rate per SNP >0.95,
minor allele frequency (MAF) >0.01, and Hardy–Weinberg
equilibrium p value >0.001. In the replication cohorts, a
similar approach was undertaken, except that samples with
call rates less than 99.5 % and genotyping success rates less
than 99 % were excluded [25].
To identify the potentially regulatory variants, we used
publicly available databases and datasets, including Reg-
ulomeDB [26] and a dataset of expression quantitative
trait loci studied in peripheral blood [27].
Statistical analysis
Continuous variables were described using mean and
standard deviation. Dichotomous and categorical vari-
ables were described using proportions. In all genetic
analyses, an additive model of effect was used. SHS was
log-transformed [log(SHS + 1)] to approximate a normal
distribution.
The effect of the SNPs on radiological joint damage
was assessed using two different models [21]. (1) In
approach 1, we analyzed the overall effect of each poly-
morphism in radiological damage, assuming a stable
effect over time (constant effect). In approach 2, we ana-
lyzed how the SNPs influenced the progression or the
slope of the radiological joint damage over time (time-
varying effect). Having this in mind, for datasets with
multiple sets of X-rays per patient (HCSC-RAC, PEARL,
PAZ, EAC, and Wichita) and to account for the within-
patient correlation between measurements, linear mixed
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regression models were used [28, 29]. Approach 1 was
carried out by analyzing the log-transformed SHS as the
dependent variable and including the following in the
model as independent variables: sex, age at symptom on-
set (in the discovery cohorts) or age at diagnosis (in the
replication cohorts), initial RA treatment strategy (using
the year at RA diagnosis as a surrogate marker; treat),
elapsed time from RA symptom onset/diagnosis to the
time of the X-ray (time), and SNP:
SHS ¼ α þ β1  sexj þ β2  agej þ β3  treatj
þ β4  timeij þ β5  SNPj þ u0j þ εij;
where i represents X-ray; j represents patient; εij is the
normally distributed error with mean 0; α, β1, β2, β3, β4,
and β5 represent the intercept and the fixed effects coef-
ficients for sex, age at symptom onset/diagnosis, initial
treatment strategy, elapsed time from symptoms onset/
diagnosis to X-ray, and polymorphism, respectively; and
u0j is the random effect per patient.
Approach 2 was carried out by introducing an inter-
action between elapsed time and polymorphism in
approach 1:
SHS ¼ α þ β1  sexj þ β2  agej þ β3
 treatj þ β4  timeij þ β5  SNPj
þ β6  timeij  SNPj þ u0j þ εij;
where β6 represents the coefficient for the interaction
between elapsed time and polymorphism.
For the dataset with only one observation per patient
(NDB cohort), approach 1 was carried out by analyzing
the log-transformed SHS using linear regression models
[30], adjusted by sex, age at diagnosis, elapsed time from
RA diagnosis to the time of the X-ray, and SNP:
SHS ¼ α þ β1  sexj þ β2  agej þ β3
 timeij þ β4  SNPj þ εij
Approach 2 was carried out using linear regression
models with the estimated yearly progression rate (total
SHS divided by number of disease year at the time of
the X-ray; YPR) as the dependent variable and sex, age
at diagnosis, and SNP as independent variables:
YPR ¼ α þ β1  sexj þ β2  agej þ β3
 SNPj þ εij
The results were back-transformed after analysis and
expressed as effect size (ES) with 95 % confidence inter-
vals (CIs). ES represents, in the constant effect analysis,
a fold increase or decrease in radiological joint damage
per copy of the minor allele that is constant over time,
regardless of sex, age, elapsed time from inception to
X-ray, or initial treatment (in HCSC-RAC, PEARL, PAZ,
and EAC cohorts). In the time-varying effect analysis, the
ES indicates the fold rate of radiological joint damage per
year per copy of the minor allele compared with the refer-
ence common genotype, regardless of sex, age, elapsed
time from inception to X-ray, or initial treatment.
The results from the discovery cohorts, the replication
cohorts, and the six overall cohorts were pooled using
inverse-variance–weighted meta-analysis to account for
differences between cohorts [31]. Between-population
heterogeneity was assessed by using the Durbin test and
calculating the I2 statistic (percentage of total variation
across studies that is due to heterogeneity rather than to
chance). Fixed or random effects models were used
according to the absence or presence of heterogeneity,
respectively. A cutoff value ≥0.4 in the I2 statistic was
used to define heterogeneity. The significance of the
pooled β-coefficients was determined by using the Z-test,
and 95 % CIs were calculated.
With regard to the pooled analysis of the rs6896969
polymorphism, the p value of the meta-analysis of the
six overall cohorts was adjusted using the Bonferroni
correction.
A fine-mapping analysis of the PTGER4 region was
performed in the HCSC-RAC, PEARL, and PAZ cohorts.
We selected those variants to be replicated in the EAC,
Wichita, and NDB cohorts, based on the p values of the
pooled analysis of the discovery cohorts, on the linkage
disequilibrium (LD) structure of the mapped region (see
Additional file 1: Figures S2 and S3), and on the location
of the variants in regions with known or predicted tran-
scriptional regulatory properties: among those with a
pooled p value <0.05, the one SNP for each LD block
(r2 > 0.9) with the lowest RegulomeDB score (the lower
the score, the higher the likelihood that the variant is
ocated in a regulatory region).
To generate a p-value threshold for the pooled analysis
of the 6 cohorts to retain an experiment-wide type I
error of 0.05, we decided to carry out a Bonferroni cor-
rection based on the number of effectively independent
SNPs tested, and in the fact that we performed a con-
stant and a time-varying effect analysis for each SNP. LD
blocks were defined by an r2 value >0.9 and a distance
limit between SNPs of 500 kb. We observed 192 LD
blocks, and because all polymorphisms were tested in two
different models, the final threshold p value was 1.3 × 10−4.
All analyses were performed using STATA version 12
(StataCorp, College Station, TX, USA) and IBM SPSS
version 15.0 software (IBM, Armonk, NY, USA).
Results
Association between PTGER4 rs6896969 SNP and
radiographic joint destruction
The demographic and clinical characteristics of the pa-
tients included in the study are shown in Table 1. We
initially analyzed the effect of the PTGER4 rs6896969
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SNP on radiological joint damage in the HCSC-RAC,
PEARL, and PAZ cohorts (Fig. 1). We observed that its
minor allele was significantly associated with lower
radiographic joint damage in the HCSC-RAC and PAZ
cohorts (p = 0.03 and p = 0.02, respectively) in the con-
stant effect analysis. The PEARL cohort also showed a
protective effect, although it was not significant (p = 0.44).
When we pooled the effects from the discovery cohorts,
meta-analysis showed a significant protective association
(fixed effects pooled p value = 8.6 × 10−4, I2 = 0). With
regard to the time-varying effect analysis, no significant
association was observed in any of the three cohorts
(see Additional file 2: Table S1).
We attempted to validate the results from the constant
effect analysis in our replication cohorts (EAC, Wichita,
and NDB) (Fig. 1). None of them showed a significant
association between the rs6896969 variant and radio-
logical joint damage (p = 0.10, p = 0.63, and p = 0.32,
respectively). Moreover, only in the EAC cohort did the
polymorphism show a protective effect. When we pooled
Table 1 Demographic and clinical characteristics of the patients with rheumatoid arthritis
Cohort
Variable HCSC-RAC PEARL PAZ EAC Wichita NDB
Total patients, n 402 81 42 597 100 567
Total sets of X-rays, n 637 210 173 3143 353 567
Female sex, n (%) 304 (75.62) 62 (76.54) 26 (61.90) 402 (67.3) 70 (70.0) 444 (78.3)
Age at diagnosis, yr, mean (SD) 57.09 (13.61) 55.39 (17.33) 53.11 (14.77) 57.1 (15.6) 49.1 (11.6) 48.7 (12.7)
Year at RA diagnosis, range 1976–2011 2000–2011 1992–2004 1993–2006 1963–1999 1980–1999
RF positivity, n (%) 260 (64.68) 47 (58.02) 35 (83.33) 342 (57.6)a – –
ACPA positivity, n (%) 167 (47.18)b 38 (47.50)c 33 (78.57) 309 (52.8)d 96 (97.0)e 452 (79.7)
Radiographic follow-up, yr 15 5 10 7 15 NA
ACPA anticitrullinated peptide antibodies, EAC Leiden Early Arthritis Clinic cohort, HCSC-RAC Hospital Clínico San Carlos rheumatoid arthritis cohort, NDB National
Databank for Rheumatic Diseases cohort, PAZ Hospital Universitario de La Paz early arthritis cohort, PEARL Princesa Early Arthritis Register Longitudinal study
cohort, RA rheumatoid arthritis, RF rheumatoid factor, SD standard deviation
aRF status missing in three patients from the EAC cohort
bACPA status missing in 60 patients from the HCSC-RAC cohort
cACPA status missing in one patient from the PEARL cohort
dACPA status missing in 12 patients from the EAC cohort
eACPA status missing in one patients from the Wichita cohort
Fig. 1 Forest plot representing the individual and pooled results of the effect of the PTGER4 rs6896969 variant in radiographic joint destruction.
CI confidence interval, EAC Leiden Early Arthritis Clinic cohort, ES effect size, HCSC-RAC Hospital Clínico San Carlos rheumatoid arthritis cohort,
NDB National Databank for Rheumatic Diseases, PAZ Hospital Universitario de La Paz early arthritis cohort, PEARL Princesa Early Arthritis Register
Longitudinal study, PTGER4 prostaglandin E receptor 4
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the results from the replication cohorts, no significant as-
sociation was observed (fixed effects model p value = 0.92,
I2 = 0). Furthermore, when we combined the six cohorts,
no significant association was observed (random effects
model p value = 0.10, I2 = 0.46) (Fig. 1).
Analysis of the PTGER4 region and radiological joint
damage
Because rs6896969 showed a significant association in
the pooled analysis of the Spanish cohorts, and because
we considered PTGER4 a good candidate gene to play a
part in RA radiological joint damage due to its immune
regulation and bone metabolism roles, we decided to
carry on and perform a fine-mapping analysis of the re-
gion around PTGER4 using available Immunochip data.
Our aim was not to refine the signal from rs6896969, as
this SNP did not show a significant association in the
overall pooled analysis, but to detect other variant(s)
that might be significantly associated with radiological
joint damage. Moreover, we decided not to restrict our
analysis to the constant effect models, although this was
the model that showed a significant association with
radiological joint damage in the Spanish cohorts.
A total of 976 SNPs were analyzed in the discovery co-
horts (HCSC-RAC, PEARL, and PAZ). In the pooled
analysis, we observed 77 variants associated with radio-
logical joint damage in the constant effect analysis and
91 SNPs in the time-varying effect analysis, with a
pooled p value <0.05 (see Additional file 2: Tables S2
and S3). Considering the LD pattern, 11 SNPs captured
all 77 constant effect analysis variants (with a mean r2 of
0.98) (Additional file 2: Table S4). We decided to include
rs1876143 as well because, although another polymorph-
ism from its LD block (rs1876140) captured the variabil-
ity better, the former had a much lower RegulomeDB
score. In the pooled analysis of the replication cohorts
or in the pooled analysis of all six cohorts, no variant
showed a significant association with radiological joint
damage (Table 2).
With regard to the time-varying effect analysis, 19
SNPs captured all 91 variants (with a mean r2 of 0.99)
(Additional file 2: Table S5). We decided to include
rs4409138 as well because it has a lower RegulomeDB
score compared with the variant that captures the vari-
ability for the LD block. In the pooled analysis of the
replication cohorts, three SNPs showed a p value <0.05
(Table 3). In the pooled analysis of the six overall co-
horts, we observed that only the rs76523431 variant
showed a significant association with radiological joint
damage below the threshold p value (fixed effects model
p value = 2.10 × 10−5, I2 = 0.13) (Fig. 2). We observed an
ES of 1.10 (95 % CI 1.05–1.14), meaning that radio-
graphic yearly progression was 10 % greater for each
copy of the minor allele.
Discussion
We analyzed, for the first time to our knowledge, the po-
tential implication of the PTGER4 gene in RA disease
severity, measured as radiological joint damage in several
cohorts of Caucasian patients. In this study, we observed
that the rs76523431 variant showed a positive and sig-
nificant association with disease severity in the time-
varying effect analysis: the more copies of the minor al-
lele, the greater the radiographic progression (more joint
damage per time unit).
Taking into account the role played by EP4 in the dif-
ferentiation of Th1 lymphocytes and in the expansion of
Th17 cells [7, 8] (both implicated in RA pathogenesis
[32]), and that the lack of Ptger4 or its blockage amelio-
rates the disease in several mouse arthritis models (colla-
gen-induced [5, 8], collagen antibody–induced [10], and
glucose-6-phosphate isomerase–induced arthritis models
[8]), we decided to analyze the role of PTGER4 in RA
severity. Several SNPs from this gene or its surrounding
region had previously been associated with other
immune-regulated diseases. rs10440635 was associated
with ankylosing spondylitis (AS) [9] in Caucasians and
with AS severity [33] in Chinese patients. Many variants
have been associated with inflammatory bowel disease.
rs11742570 [34–36], rs17234657 [37–39], rs4495224 [40],
rs7720838 [40], rs4613763 [41], rs9292777 [41, 42], and
rs1373692 [43, 44] are risk factors for Crohn’s disease,
although some associations have not always been repli-
cated [45]. However, rs4613763 [46, 47] and rs6451493
[48] have been associated with ulcerative colitis. Several
variants have also been associated with multiple sclerosis
(rs9292777 [49] and rs4613763 [50]), including rs6896969
[16], the SNP initially analyzed in the present study. The
influence of rs17234657 and rs6871834 in RA risk was
also analyzed, with no significant results observed [38].
With regard to the variant significantly associated with
radiographic progression in this study, it has not previ-
ously been associated with any other immune-mediated
diseases. Moreover, other SNPs in complete LD with
rs76523431 (rs114152040, rs113233093, rs116154382,
and rs112110624) also have not previously been associated
with any condition (data obtained from SNAP in 1000 Ge-
nomes Project Pilot 1 [51]). However, one of those SNPs
(rs112110624) is located in the binding site of two tran-
scription factors (TFAP2A and TFAP2C) [26]. It is possible
that this variant affects the binding of any of these tran-
scription factors, and therefore it could alter the expression
of EP4. We could speculate that rs112110624 is the poly-
morphism driving the association of PTGER4 with RA se-
verity, although it cannot be ruled out that rs76523431 or
any other SNP in LD is the real causal variant of this asso-
ciation. We also used miRBASE [52] to assess if any SNP
was located in or near a described miRNA. Unfortunately,
no miRNA has been described in that region.
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Table 2 Candidate single-nucleotide polymorphisms selected for replication from constant effect analysis
Discovery cohort Replication cohort Overall cohort (n = 6)
SNP Position RegulomeDB
score
Westra et al. [27]
cis-eQTL p value (gene)
Pooled ES (95 % CI) Pooled p valuea I2 value Pooled ES (95 % CI) Pooled
p valuea
I2 value Pooled ES (95 % CI) Pooled
p-valuea
I2 value
rs348561 40312392 5 – 0.82 (0.67–0.996) 0.05 0.03 0.99 (0.90–1.08) 0.81 0 0.94 (0.86–1.04) 0.23 0.23
rs115430320 40318274 – – 0.55 (0.39–0.80) 0.001 0 0.96 (0.80–1.15) 0.68 0.34 0.86 (0.74–1.02) 0.19 0.51
rs348601 40320006 5 – 0.86 (0.74–0.999) 0.05 0 0.94 (0.87–1.02) 0.45 0.42 0.92 (0.86–0.99) 0.03 0.23
rs394213 40333751 3a – 0.76 (0.63–0.91) 0.003 0 0.97 (0.88–1.06) 0.45 0 0.92 (0.85–1.0005) 0.05 0.35
rs35870239 40344952 – – 0.74 (0.59–0.93) 0.01 0.15 0.98 (0.88–1.09) 0.69 0 0.93 (0.84–1.02) 0.13 0.35
rs62359777 40350759 6 – 0.81 (0.68–0.95) 0.01 0 0.96 (0.86–1.08) 0.50 – 0.91 (0.83–0.999) 0.05 0.38
rs75248677 40365721 5 – 0.71 (0.56–0.90) 0.005 0.38 0.94 (0.84–1.07) 0.35 0 0.89 (0.80–0.99) 0.04 0.36
rs56049341 40376614 5 – 2.44 (1.28–4.66) 0.01 0 1.34 (0.72–2.51) 0.36 – 1.79 (1.14–2.81) 0.01 0
rs56027413 40382134 2b – 1.18 (1.003–1.40) 0.05 0 1.03 (0.94–1.12) 0.55 0.19 1.06 (0.98–1.15) 0.14 0.02
rs12520940 40382428 4 – 0.81 (0.67–0.98) 0.03 0.33 1.00 (0.91–1.10) 0.98 0 0.96 (0.88–1.05) 0.35 0.31
rs1876140 40505752 – 3.68x10–15 (PTGER4) 0.80 (0.66–0.97) 0.03 0 1.05 (0.96–1.16) 0.36 0.43 0.997 (0.91–1.09) 0.75 0.52
rs1876143 40521648 2b 7.32x10–13 (PTGER4) 0.80 (0.66–0.96) 0.02 0 1.06 (0.96–1.17) 0.25 0.12 0.999 (0.92–1.09) 0.68 0.52
ES effect size, PTGER4 prostaglandin E receptor 4, SNP single-nucleotide polymorphism
Data are based on pooled analysis in the discovery cohort, replication cohort, and all six overall cohorts
aRandom effects p value was used if I2 value was ≥0.4. Otherwise, fixed effects p value was used
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Table 3 Candidate single-nucleotide polymorphisms selected for replication from the time-varying effect analysis
Discovery cohort Replication cohort Overall cohort (n = 6)
SNP Position RegulomeDB
score
Westra et al. [27]
cis p value (gene)
Pooled ES (95 % CI) Pooled
p valuea
I2 value Pooled ES (95 % CI) Pooled
p valuea
I2 value Pooled ES (95 % CI) Pooled p valuea I2 value
rs80058440 40350930 6 – 1.05 (1.01–1.08) 0.01 0 0.99 (0.97–1.02) 0.62 – 1.01 (0.99–1.03) 0.18 0.50
rs6451489 40357663 5 – 0.97 (0.95–0.99) 0.01 0.15 1.01 (0.99–1.02) 0.40 0 0.99 (0.98–1.01) 0.46 0.43
rs12515934 40376930 2b – 1.05 (1.01–1.08) 0.004 0.27 1.01 (0.98–1.03) 0.54 0 1.02 (1.002–1.04) 0.03 0.24
rs12520940 40382428 4 – 1.04 (1.01–1.07) 0.01 0 0.99 (0.97–1.01) 0.25 0 1.003 (0.99–1.02) 0.53 0.47
rs13160782 40428061 4 – 1.04 (1.01–1.06) 0.01 0 1.01 (1.00–1.03) 0.16 0.28 1.02 (1.005–1.03) 0.01 0.05
rs76523431 40443657 6 – 1.10 (1.01–1.19) 0.02 0.36 1.10 (1.04–1.15) 3.32 × 10−4 0.24 1.10 (1.05–1.14) 2.10 × 10−5 0.13
rs78607701 40447491 4 – 0.93 (0.89–0.98) 0.004 0 0.99 (0.95–1.03) 0.51 0 0.97 (0.94–0.99) 0.02 0
rs58752461 40481432 4 – 0.97 (0.94–0.99) 0.03 0 0.98 (0.96–1.00) 0.08 0 0.98 (0.96–0.99) 0.01 0
rs4587119 40492734 – 1.16 × 10−16 (PTGER4) 1.04 (1.004–1.07) 0.03 0.31 1.00 (0.98–1.03) 0.87 0 1.01 (0.99–1.03) 0.14 0.27
rs13181935 40493646 – 6.88 × 10−11 (PTGER4) 1.05 (1.01–1.08) 0.01 0 1.01 (0.98–1.03) 0.61 0 1.02 (1.0002–1.04) 0.05 0.17
rs7707931 40496930 6 3.68 × 10–13 (PTGER4) 1.03 (1.004–1.06) 0.02 0 1.01 (0.99–1.02) 0.58 0 1.01 (0.99–1.03) 0.08 0
rs74630635 40510535 – – 1.05 (1.01–1.10) 0.02 0 1.05 (1.01–1.09) 0.01 0.22 1.05 (1.02–1.08) 6.40 × 10−4 0
rs7705019 40587804 3a – 1.04 (1.01–1.08) 0.03 0.49 1.01 (0.99–1.03) 0.40 0 1.02 (1.003–1.04) 0.03 0.36
rs2174550 40602383 – – 0.93 (0.88–0.99) 0.04 0.33 1.00 (0.98–1.03) 0.83 0.44 0.99 (0.97–1.02) 0.15 0.53
rs4409138 40603605 2b – 1.04 (1.01–1.07) 0.01 0.37 1.01 (0.99–1.03) 0.37 0 1.02 (1.002–1.04) 0.03 0.24
rs924967 40615122 – 2.36 × 10−11 (PTGER4) 1.04 (1.01–1.07) 0.01 0.26 1.01 (0.99–1.03) 0.38 0 1.02 (1.002–1.04) 0.03 0.18
rs76504641 40624582 6 – 0.96 (0.92–0.99) 0.02 0 1.00 (0.98–1.02) 0.98 0 0.99 (0.97–1.01) 0.28 0.35
rs4432939 40671099 – – 0.97 (0.95–0.99) 0.03 0 0.98 (0.96–1.00) 0.05 0 0.98 (0.96–0.99) 0.004 0
rs45480797 40680964 2a – 0.95 (0.91–0.99) 0.01 0 0.98 (0.95–1.01) 0.24 0 0.97 (0.95–0.99) 0.02 0
rs78733746 40727730 4 – 0.93 (0.88–0.99) 0.02 0 1.00 (0.96–1.04) 0.93 0 0.98 (0.95–1.01) 0.19 0
CI confidence interval, ES effect size, PTGER4 prostaglandin E receptor 4, SNP single-nucleotide polymorphism
Data are based on pooled analysis in the discovery cohort, replication cohort, and all six overall cohorts
aRandom effects p value was used if I2 value was ≥0.4. Otherwise, fixed effects p-value was used
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With regard to the limitations of our study, it is import-
ant to point out the presence of clinical heterogeneity
among cohorts, such as differences in cohort size, number
of X-rays per patient, year of disease onset, presence of
ACPA, follow-up duration, and whether the feet were in-
cluded in the radiological joint damage assessment. To ac-
count for these factors, first we analyzed each cohort
individually, adjusting for most of these variables. Then
we combined the results with inverse-variance–weighted
meta-analysis, which gives, in the pooled results, a higher
weight to those cohorts with more precise results.
Also, X-rays in some cohorts were obtained at stan-
dardized time points (PEARL, PAZ, EAC, and Wichita),
whereas in others (HCSC-RAC and NDB) X-rays were
taken when requested by the patient’s rheumatologist as
deemed necessary and not as part of a protocol.
Finally, the PTGER4 rs76523431 variant has a low
MAF (HCSC-RAC 1.8 %, PEARL 4.3 %, PAZ 1.2 %, EAC
2.1 %, NDB 2.0 %, and Wichita 1.5 %), and therefore it
has a lower power to detect weak effects than loci with
higher MAFs. However, it is important to take into
account that this is an exploratory result, and future
studies need to be performed to verify that this is not a
spurious association.
Conclusions
The results reported in this article suggest that the
PTGER4 variant rs76523431 could be associated with
greater radiographic progression in Caucasian patients
with RA. Further studies are necessary to fully elucidate
the effect of this and other SNPs in PTGER4 expression.
Additional files
Additional file 1: Figure S1. Region analyzed in the fine-mapping
analysis. Figure S2. Linkage disequilibrium blocks among the significant
SNPs (pooled p < 0.05) from the constant effect analysis. Figure S3. Link-
age disequilibrium blocks among the significant SNPs (pooled p < 0.05)
from the time-varying effect analysis. (DOC 845 kb)
Additional file 2: Table S1. Multivariate linear mixed models to analyze
the time-varying effect of the PTGER4 rs6896969 variant in radiographic
joint damage of the HCSC-RAC, PEARL, and PAZ cohorts. Table S2.
Single-nucleotide polymorphisms with p < 0.05 in the constant effect
pooled analysis from the discovery cohorts. Table S3. Single-nucleotide
polymorphisms with p < 0.05 in the time-varying effect pooled analysis
from the discovery cohorts. Table S4. Single-nucleotide polymorphisms
selected for replication in the constant effect analysis and their associations
with radiological joint damage in the six cohorts. Table S5. Single-nucleo-
tide polymorphisms selected for replication in the time-varying effect ana-
lysis and their associations with radiological joint damage in the six cohorts.
(DOC 325 kb)
Abbreviations
ACPA: anticitrullinated peptide antibodies; AS: ankylosing spondylitis;
CI: confidence interval; EAC: Leiden Early Arthritis Clinic cohort;
EP2: prostaglandin E2 receptor; EP4: prostaglandin E receptor 4; ES: effect size;
HCSC-RAC: Hospital Clínico San Carlos rheumatoid arthritis cohort;
ICC: intraclass correlation coefficient; IL: interleukin; LD: linkage disequilibrium;
MAF: minor allele frequency; NDB: National Databank for Rheumatic Diseases;
NSAID: nonsteroidal anti-inflammatory drugs; PAZ: Hospital Universitario de
La Paz early arthritis cohort; PEARL: Princesa Early Arthritis Register
Longitudinal study; PTGER4: prostaglandin E receptor 4; RA: rheumatoid
arthritis; RF: rheumatoid factor; SD: standard deviation; SHS: Sharp/van der
Heijde score; SNP: single-nucleotide polymorphism; Th: T helper cell.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LRR and BFG participated in study conception and design. LRR, JIC, AB,
HWvS, and IGA participated in data collection. LRR, HWvS, AHMvdHvM, FDC,
Fig. 2 Forest plot representing the individual and pooled results of the effect of the PTGER4 rs76523431 variant in radiographic joint destruction.
CI confidence interval, EAC Leiden Early Arthritis Clinic cohort, ES effect size, HCSC-RAC Hospital Clínico San Carlos rheumatoid arthritis cohort,
NDB National Databank for Rheumatic Diseases, PAZ Hospital Universitario de La Paz early arthritis cohort, PEARL Princesa Early Arthritis Register
Longitudinal study, PTGER4 prostaglandin E receptor 4
Rodriguez-Rodriguez et al. Arthritis Research & Therapy  (2015) 17:306 Page 9 of 11
and JM participated in data analysis. All authors contributed to interpretation
of the data. LRR and BFG drafted the manuscript, and all other authors
revised it critically. All authors read and approved the final manuscript and
agree to be accountable for all aspects of the work.
Acknowledgments
We thank Peter K. Gregersen at the Feinstein Institute for Medical Research
for providing access to data from the Wichita and NDB cohorts. We also
thank all the patients with RA for making this study possible. Also, we are
grateful to Alicia Moreno and Mercedes Montaner, who helped with the
PTGER4 TaqMan assay genotyping. This work was supported by the Instituto
de Salud Carlos III (ISCIII), Ministry of Health, Spain [Miguel Servet research
contract CP12/03129 (to LRR); Fondo de Investigaciones Sanitarias PI11/02413;
and Red de Investigación en Inflamación y Enfermedades Reumáticas
RD12/0009/0004, RD12/0009/0011, and RD12/0009/0017]. The funders had
no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Author details
1Rheumatology Department and Heath Research Institute (IdISSC), Hospital
Clinico San Carlos, c/o Prof. Martin Lagos s/n, 28040 Madrid, Spain.
2Rheumatology Department, Hospital Universitario y Politécnico La Fe,
Valencia, Spain. 3Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC,
Granada, Spain. 4Rheumatology Department and Heath Research Institute
(Idipaz), Hospital Universitario de La Paz, Madrid, Spain. 5Department of
Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands.
6Rheumatology Service and Heath Research Institute (IP), Hospital
Universitario de La Princesa, Madrid, Spain.
Received: 25 May 2015 Accepted: 20 October 2015
References
1. Morel J, Combe B. How to predict prognosis in early rheumatoid arthritis.
Best Pract Res Clin Rheumatol. 2005;19:137–46.
2. Radner H, Smolen JS, Aletaha D. Comorbidity affects all domains of physical
function and quality of life in patients with rheumatoid arthritis.
Rheumatology (Oxford). 2011;50:381–8.
3. van Nies JAB, Krabben A, Schoones JW, Huizinga TWJ, Kloppenburg M,
van der Helm-van Mil AHM. What is the evidence for the presence of a
therapeutic window of opportunity in rheumatoid arthritis? A systematic
literature review. Ann Rheum Dis. 2014;73:861–70.
4. Inoue H, Takamori M, Shimoyama Y, Ishibashi H, Yamamoto S, Koshihara Y.
Regulation by PGE2 of the production of interleukin-6, macrophage colony
stimulating factor, and vascular endothelial growth factor in human synovial
fibroblasts. Br J Pharmacol. 2002;136:287–95.
5. Honda T, Segi-Nishida E, Miyachi Y, Narumiya S. Prostacyclin-IP signaling
and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in
mouse collagen-induced arthritis. J Exp Med. 2006;203:325–35.
6. Sheibanie AF, Yen JH, Khayrullina T, Emig F, Zhang M, Tuma R, et al. The
proinflammatory effect of prostaglandin E2 in experimental inflammatory
bowel disease is mediated through the IL-23→ IL-17 axis. J Immunol.
2007;178:8138–47.
7. Yao C, Sakata D, Esaki Y, Li Y. Prostaglandin E2–EP4 signaling promotes
immune inflammation through TH1 cell differentiation and TH17 cell
expansion. Nat Med. 2009;15:633–40.
8. Chen Q, Muramoto K, Masaaki N, Ding Y, Yang H, Mackey M, et al. A novel
antagonist of the prostaglandin E2 EP4 receptor inhibits Th1 differentiation
and Th17 expansion and is orally active in arthritis models. Br J Pharmacol.
2010;160:292–310.
9. Evans DM, Spencer CCA, Pointon JJ, Su Z, Harvey D, Kochan G, et al.
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates
peptide handling in the mechanism for HLA-B27 in disease susceptibility.
Nat Genet. 2011;43:761–7.
10. McCoy JM, Wicks JR, Audoly LP. The role of prostaglandin E2 receptors in
the pathogenesis of rheumatoid arthritis. J Clin Invest. 2002;110:651–8.
11. Yoshida K, Oida H, Kobayashi T, Maruyama T, Tanaka M, Katayama T, et al.
Stimulation of bone formation and prevention of bone loss by prostaglandin E
EP4 receptor activation. Proc Natl Acad Sci U S A. 2002;99:4580–5.
12. Ono K, Akatsu T, Kugai N, Pilbeam CC, Raisz LG. The effect of deletion of
cyclooxygenase-2, prostaglandin receptor EP2, or EP4 in bone marrow cells
on osteoclasts induced by mouse mammary cancer cell lines. Bone.
2003;33:798–804.
13. Li X, Okada Y, Pilbeam CC, Lorenzo JA, Kennedy CR, Breyer RM, et al.
Knockout of the murine prostaglandin EP2 receptor impairs
osteoclastogenesis in vitro. Endocrinology. 2000;141:2054–61.
14. Yoshida T, Horiuchi T, Sakamoto H, Inoue H, Takayanagi H, Nishikawa T,
et al. Production of parathyroid hormone-related peptide by synovial
fibroblasts in human osteoarthritis. FEBS Lett. 1998;433:331–4.
15. Lettre G, Rioux JD. Autoimmune diseases: insights from genome-wide
association studies. Hum Mol Genet. 2008;17:R116–21.
16. De Jager PL, Jia X, Wang J, de Bakker PIW, Ottoboni L, Aggarwal NT, et al.
Meta-analysis of genome scans and replication identify CD6, IRF8 and
TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet.
2009;41:776–82.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al.
The American Rheumatism Association 1987 revised criteria for the
classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
18. Rodriguez-Rodriguez L, Jover-Jover JA, Fontsere O, Peña-Blanco RC, León L,
Fernández-Gutierrez B, et al. Leflunomide discontinuation in rheumatoid
arthritis and influence of associated disease-modifying anti-rheumatic drugs:
a survival analysis. Scand J Rheumatol. 2013;42:433–6.
19. González-Álvaro I, Ortiz AM, Alvaro-Gracia JM, Castañeda S, Díaz-Sánchez B,
Carvajal I, et al. Interleukin 15 levels in serum may predict a severe disease
course in patients with early arthritis. PLoS One. 2011;6:e29492.
20. Richi P, Balsa A, Muñoz-Fernández S, Villaverde V, Fernández-Prada M,
Vicario JL, et al. Factors related to radiological damage in 61 Spaniards with
early rheumatoid arthritis. Ann Rheum Dis. 2002;61:270–2.
21. de Rooy DPC, van der Linden MPM, Knevel R, Huizinga TWJ,
van der Helm-van Mil AHM. Predicting arthritis outcomes—what can
be learned from the Leiden Early Arthritis Clinic? Rheumatology
(Oxford). 2011;50:93–100.
22. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and
mortality in patients with rheumatoid arthritis: a prospective study. Lancet.
2002;359:1173–7.
23. Wolfe F, Michaud K. The National Data Bank for rheumatic diseases: a multi-
registry rheumatic disease data bank. Rheumatology (Oxford). 2011;50:16–24.
24. Cortes A, Brown MA. Promise and pitfalls of the Immunochip. Arthritis Res
Ther. 2011;13:101.
25. de Rooy DPC, Zhernakova A, Tsonaka R, Willemze A, Kurreeman BAS, Trynka G,
et al. A genetic variant in the region of MMP-9 is associated with serum levels
and progression of joint damage in rheumatoid arthritis. Ann Rheum Dis.
2014;73:1163–9.
26. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, et al.
Annotation of functional variation in personal genomes using RegulomeDB.
Genome Res. 2012;22:1790–7.
27. Westra HJ, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J, et al.
Systematic identification of trans eQTLs as putative drivers of known disease
associations. Nat Genet. 2013;45:1238–43.
28. van der Helm-van Mil AHM, Knevel R, van der Heijde D, Huizinga TWJ. How
to avoid phenotypic misclassification in using joint destruction as an
outcome measure for rheumatoid arthritis? Rheumatology (Oxford).
2010;49:1429–35.
29. Knevel R, Tsonaka R, le Cessie S, van der Linden MPM, Huizinga TWJ, van
der Heijde DMFM, et al. Comparison of methodologies for analysing the
progression of joint destruction in rheumatoid arthritis. Scand J Rheumatol.
2013;42:182–9.
30. Strand V, Landéwé R, van der Heijde D. Using estimated yearly progression
rates to compare radiographic data across recent randomised controlled
trials in rheumatoid arthritis. Ann Rheum Dis. 2002;61 Suppl 2:ii64–6.
31. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials.
1986;7:177–88.
32. Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and
inflammatory diseases. Autoimmun Rev. 2014;13:668–77.
33. Chai W, Lian Z, Chen C, Liu J, Shi LL, Wang Y. JARID1A, JMY, and PTGER4
polymorphisms are related to ankylosing spondylitis in Chinese Han
patients: a case-control study. PLoS One. 2013;8:e74794.
34. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al.
Host–microbe interactions have shaped the genetic architecture of
inflammatory bowel disease. Nature. 2012;491:119–24.
35. Julià A, Domènech E, Ricart E, Tortosa R, García-Sánchez V, Gisbert JP, et al.
A genome-wide association study on a southern European population
Rodriguez-Rodriguez et al. Arthritis Research & Therapy  (2015) 17:306 Page 10 of 11
identifies a new Crohn’s disease susceptibility locus at RBX1-EP300. Gut.
2013;62:1440–5.
36. Franke A, McGovern DPB, Barrett JC, Wang K, Radford-Smith GL, Ahmad T,
et al. Genome-wide meta-analysis increases to 71 the number of confirmed
Crohn’s disease susceptibility loci. Nat Genet. 2010;42:1118–25.
37. Wellcome Trust Case Control Consortium. Genome-wide association study
of 14,000 cases of seven common diseases and 3,000 shared controls.
Nature. 2007;447:661–78.
38. Perdigones N, Martín E, Robledo G, Lamas JR, Taxonera C, Díaz-Rubio M,
et al. Study of chromosomal region 5p13.1 in Crohn’s disease, ulcerative
colitis, and rheumatoid arthritis. Hum Immunol. 2010;71:826–8.
39. Weersma RK, Stokkers PCF, Cleynen I, Wolfkamp SCS, Henckaerts L,
Schreiber S, et al. Confirmation of multiple Crohn’s disease susceptibility loci
in a large Dutch-Belgian cohort. Am J Gastroenterol. 2009;104:630–8.
40. Glas J, Seiderer J, Czamara D, Pasciuto G, Diegelmann J, Wetzke M, et al.
PTGER4 expression-modulating polymorphisms in the 5p13.1 region
predispose to Crohn’s disease and affect NF-κB and XBP1 binding sites.
PLoS One. 2012;7:e52873.
41. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, et al.
Genome-wide association defines more than 30 distinct susceptibility loci
for Crohn’s disease. Nat Genet. 2008;40:955–62.
42. Kenny EE, Pe’er I, Karban A, Ozelius L, Mitchell AA, Ng SM, et al. A genome-
wide scan of Ashkenazi Jewish Crohn’s disease suggests novel susceptibility
loci. PLoS Genet. 2012;8:e1002559.
43. Peter I, Mitchell AA, Ozelius L, Erazo M, Hu J, Doheny D, et al. Evaluation
of 22 genetic variants with Crohn’s disease risk in the Ashkenazi Jewish
population: a case-control study. BMC Med Genet. 2011;12:63.
44. Libioulle C, Louis E, Hansoul S, Sandor C, Farnir F, Franchimont D, et al.
Novel Crohn disease locus identified by genome-wide association maps to
a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet.
2007;3:e58.
45. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, et al.
Genome-wide association study identifies new susceptibility loci for Crohn
disease and implicates autophagy in disease pathogenesis. Nat Genet.
2007;39:596–604.
46. Latiano A, Palmieri O, Latiano T, Corritore G, Bossa F, Martino G, et al.
Investigation of multiple susceptibility loci for inflammatory bowel disease
in an Italian cohort of patients. PLoS One. 2011;6:e22688.
47. McGovern DPB, Gardet A, Törkvist L, Goyette P, Essers J, Taylor KD, et al.
Genome-wide association identifies multiple ulcerative colitis susceptibility
loci. Nat Genet. 2010;42:332–7.
48. Anderson CA, Boucher G, Lees CW, Franke A, D’Amato M, Taylor KD, et al.
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing
the number of confirmed associations to 47. Nat Genet. 2011;43:246–52.
49. Matesanz F, González-Pérez A, Lucas M, Sanna S, Gayán J, Urcelay E, et al.
Genome-wide association study of multiple sclerosis confirms a novel locus
at 5p13.1. PLoS One. 2012;7:e36140.
50. Sawcer S, Hellenthal G, Pirinen M, Spencer CCA, Patsopoulos NA,
Moutsianas L, et al. Genetic risk and a primary role for cell-mediated
immune mechanisms in multiple sclerosis. Nature. 2011;476:214–9.
51. SNP Annotation and Proxy Search. https://www.broadinstitute.org/mpg/
snap/doc.php.
52. miRBase: the microRNA database. http://www.mirbase.org/search.shtml.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Rodriguez-Rodriguez et al. Arthritis Research & Therapy  (2015) 17:306 Page 11 of 11
